| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigations |
1 Division of Nuclear Medicine, University of Washington, Seattle, Washington
2 Division of Medical Oncology, University of Washington, Seattle, Washington
3 Department of Pathology, University of Washington, Seattle, Washington
Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy followed by definitive surgery. The factors influencing the response of LABC to presurgical chemotherapy are incompletely understood. To characterize in vivo tumor biology in patients with LABC, we measured pretherapy blood flow and glucose metabolism in LABC, compared measurements with clinical and pathologic parameters, and examined blood flow and response to subsequent neoadjuvant chemotherapy. Methods: Thirty-seven patients with newly diagnosed LABC underwent 18F-FDG and 15O-water PET imaging. Thirty-one of these patients underwent neoadjuvant chemotherapy, and response was evaluated by serial measurements of tumor size and pathologic examination after definitive surgery after chemotherapy. Tumor metabolism was estimated from graphic analysis of dynamic 18F-FDG studies and was expressed as the metabolic rate of 18F-FDG (MRFDG). Blood flow was estimated from dynamic images after bolus 15O-water injection using a 1-compartment model. Tumor blood flow and metabolism were compared with clinical and pathologic parameters and with response to chemotherapy. Results: Both blood flow and metabolism were significantly higher in tumor than in normal breast. Tumor blood flow and metabolism were correlated but highly variable. There were weak associations of metabolism with patient age and tumor grade and of blood flow with estrogen receptor status. There was a statistically significant trend for patients with a high MRFDG to have a poorer response to therapy (P = 0.001). Response was not significantly correlated with any other parameters. A low ratio of MRFDG to blood flow was the best predictor of macroscopic complete response (CR) (P = 0.02 vs. non-CR). Preliminary analysis of patient follow-up showed the ratio of MRFDG to blood flow to also be predictive of disease-free survival. Conclusion: Despite uniformly large tumor size, blood flow and metabolism in LABC are highly variable. High glucose metabolism predicts a poor response to neoadjuvant chemotherapy, and low MRFDG relative to blood flow is a predictor of CR. Further work is needed to elucidate the biologic mechanisms underlying these findings.
Key Words: PET • neoadjuvant chemotherapy • breast cancer • 18F-FDG • 15O-water • response to therapy
This article has been cited by other articles:
|
|
 |
|
  J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions J. Nucl. Med., May 1, 2009; 50(5): 738 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Avril, S. Sassen, and R. Roylance Response to Therapy in Breast Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 55S - 63S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kotz, C. West, A. Saleem, T. Jones, and P. Price Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue Mol. Cancer Ther., February 1, 2009; 8(2): 303 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Lodge, H. A. Jacene, R. Pili, and R. L. Wahl Reproducibility of Tumor Blood Flow Quantification with 15O-Water PET J. Nucl. Med., October 1, 2008; 49(10): 1620 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Dunnwald, J. R. Gralow, G. K. Ellis, R. B. Livingston, H. M. Linden, J. M. Specht, R. K. Doot, T. J. Lawton, W. E. Barlow, B. F. Kurland, et al. Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer J. Clin. Oncol., September 20, 2008; 26(27): 4449 - 4457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bisdas, K. Spicer, and Z. Rumboldt Whole-Tumor Perfusion CT Parameters and Glucose Metabolism Measurements in Head and Neck Squamous Cell Carcinomas: A Pilot Study Using Combined Positron-Emission Tomography/CT Imaging AJNR Am. J. Neuroradiol., August 1, 2008; 29(7): 1376 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. de Langen, V. E. M. van den Boogaart, J. T. Marcus, and M. Lubberink Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow Oncologist, June 1, 2008; 13(6): 631 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Mullani, R. S. Herbst, R. G. O'Neil, K. L. Gould, B. J. Barron, and J. L. Abbruzzese Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow J. Nucl. Med., April 1, 2008; 49(4): 517 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Wolff, D. Berry, L. A. Carey, M. Colleoni, M. Dowsett, M. Ellis, J. E. Garber, D. Mankoff, S. Paik, L. Pusztai, et al. Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 806 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Rosen, W. B. Eubank, and D. A. Mankoff FDG PET, PET/CT, and Breast Cancer Imaging RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Kuhl Current Status of Breast MR Imaging * Part 2. Clinical Applications Radiology, September 1, 2007; 244(3): 672 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Doot, L. K. Dunnwald, E. K. Schubert, M. Muzi, L. M. Peterson, P. E. Kinahan, B. F. Kurland, and D. A. Mankoff Dynamic and Static Approaches to Quantifying 18F-FDG Uptake for Measuring Cancer Response to Therapy, Including the Effect of Granulocyte CSF J. Nucl. Med., June 1, 2007; 48(6): 920 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tafra Positron Emission Tomography (PET) and Mammography (PEM) for Breast Cancer: Importance to Surgeons Ann. Surg. Oncol., January 1, 2007; 14(1): 3 - 13. [Full Text] [PDF]
|
|
|
|
|
|
C. Rousseau, A. Devillers, C. Sagan, L. Ferrer, B. Bridji, L. Campion, M. Ricaud, E. Bourbouloux, I. Doutriaux, M. Clouet, et al. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography J. Clin. Oncol., December 1, 2006; 24(34): 5366 - 5372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Semple, R. Staff, S. Heys, T. Redpath, A. Welch, T. Ahearn, A. Hutcheon, and F. Gilbert Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration Ann. Onc., September 1, 2006; 17(9): 1393 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Linden, S. A. Stekhova, J. M. Link, J. R. Gralow, R. B. Livingston, G. K. Ellis, P. H. Petra, L. M. Peterson, E. K. Schubert, L. K. Dunnwald, et al. Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2793 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Stewart, X. Chen, J. Hadway, and T.-Y. Lee Correlation between Hepatic Tumor Blood Flow and Glucose Utilization in a Rabbit Liver Tumor Model Radiology, June 1, 2006; 239(3): 740 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Miller, M. Miller, S. Mehrotra, B. Agarwal, B. H. Mock, Q.-H. Zheng, S. Badve, G. D. Hutchins, and G. W. Sledge Jr. A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171 Clin. Cancer Res., January 1, 2006; 12(1): 281 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C M L West and N Charnley The potential of PET to increase understanding of the biological basis of tumour and normal tissue response to radiotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 50 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhu, E. B. Cronin, A. A. Currier, H. S. Vine, M. Huang, N. Chen, and C. Xu Benign versus Malignant Breast Masses: Optical Differentiation with US-guided Optical Imaging Reconstruction Radiology, October 1, 2005; 237(1): 57 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. M. van Laarhoven, L.-F. de Geus-Oei, B. Wiering, J. Lok, M. Rijpkema, J. H. A. M. Kaanders, P. F. M. Krabbe, T. Ruers, C. J. A. Punt, A. J. van der Kogel, et al. Gadopentetate Dimeglumine and FDG Uptake in Liver Metastases of Colorectal Carcinoma as Determined with MR Imaging and PET Radiology, October 1, 2005; 237(1): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Roubidoux, G. L. LeCarpentier, J. B. Fowlkes, B. Bartz, D. Pai, S. P. Gordon, A. F. Schott, T. D. Johnson, and P. L. Carson Sonographic Evaluation of Early-Stage Breast Cancers That Undergo Neoadjuvant Chemotherapy J. Ultrasound Med., July 1, 2005; 24(7): 885 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schroeder, H. Yuan, B. L. Viglianti, C. Peltz, S. Asopa, Z. Vujaskovic, and M. W. Dewhirst Spatial Heterogeneity and Oxygen Dependence of Glucose Consumption in R3230Ac and Fibrosarcomas of the Fischer 344 Rat Cancer Res., June 15, 2005; 65(12): 5163 - 5171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Quon and S. S. Gambhir FDG-PET and Beyond: Molecular Breast Cancer Imaging J. Clin. Oncol., March 10, 2005; 23(8): 1664 - 1673. [Full Text] [PDF]
|
|
|
|
|
|
J. Tseng, L. K. Dunnwald, E. K. Schubert, J. M. Link, S. Minoshima, M. Muzi, and D. A. Mankoff 18F-FDG Kinetics in Locally Advanced Breast Cancer: Correlation with Tumor Blood Flow and Changes in Response to Neoadjuvant Chemotherapy J. Nucl. Med., November 1, 2004; 45(11): 1829 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Rajendran, D. A. Mankoff, F. O'Sullivan, L. M. Peterson, D. L. Schwartz, E. U. Conrad, A. M. Spence, M. Muzi, D. G. Farwell, and K. A. Krohn Hypoxia and Glucose Metabolism in Malignant Tumors: Evaluation by [18F]Fluoromisonidazole and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Clin. Cancer Res., April 1, 2004; 10(7): 2245 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wells, T. Jones, and P. Price Assessment of Inter- and Intrapatient Variability in C15O2 Positron Emission Tomography Measurements of Blood Flow in Patients with Intra-abdominal Cancers Clin. Cancer Res., December 15, 2003; 9(17): 6350 - 6356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G R Laking and P M Price Positron emission tomographic imaging of angiogenesis and vascular function Br. J. Radiol., December 1, 2003; 76(suppl_1): S50 - S59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mankoff, L. K. Dunnwald, J. R. Gralow, G. K. Ellis, E. K. Schubert, J. Tseng, T. J. Lawton, H. M. Linden, and R. B. Livingston Changes in Blood Flow and Metabolism in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy J. Nucl. Med., November 1, 2003; 44(11): 1806 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Biersack and H. Palmedo Locally Advanced Breast Cancer: Is PET Useful for Monitoring Primary Chemotherapy? J. Nucl. Med., November 1, 2003; 44(11): 1815 - 1817. [Full Text] [PDF]
|
|
|
|
|
|
B. O. Anderson Pathologic Response to Preoperative Systemic Therapy: The New Biological Paradigm for Predicting Outcome and Planning Therapy Ann. Surg. Oncol., August 1, 2003; 10(7): 713 - 715. [Full Text] [PDF]
|
|
|
|
|
|
S. Beaulieu, P. Kinahan, J. Tseng, L. K. Dunnwald, E. K. Schubert, P. Pham, B. Lewellen, and D. A. Mankoff SUV Varies with Time After Injection in 18F-FDG PET of Breast Cancer: Characterization and Method to Adjust for Time Differences J. Nucl. Med., July 1, 2003; 44(7): 1044 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mankoff, L. K. Dunnwald, and P. Kinahan Are We Ready for Dedicated Breast Imaging Approaches? J. Nucl. Med., April 1, 2003; 44(4): 594 - 595. [Full Text] [PDF]
|
|
|
|
|
|
L. Kostakoglu and S. J. Goldsmith 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 224 - 239. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
